|
|
楼主 |
发表于 23-1-2021 10:15 AM
|
显示全部楼层
本帖最后由 icy97 于 26-3-2021 08:24 AM 编辑
Type | Reply to Query | Reply to Bursa Malaysia's Query Letter - Reference ID | IQL-24092020-00001 | Subject | REGISTRATION, MANUFACTURING AND COMMERCIALISATION AGREEMENT BETWEEN SOLUTION GROUP BERHAD ("SGB" OR "COMPANY") AND CANSINO BIOLOGICS INC. ("AGREEMENT") | Description | Reply to Query | Query Letter Contents | We refer to your Company’s announcement dated 23 September 2020, in respect of the aforesaid matter.
In this connection, kindly furnish Bursa Securities with the following additional information for public release:- 1) The tenure of the Agreement.
2) The expected date of registration with the National Pharmaceutical Regulatory Agency. | The Company wishes to provide the following additional information:
1) The tenure of the Agreement is 5 years. 2) The expected date of registration with the National Pharmaceutical Regulatory Agency is expected to take about 6 months from now.
This announcement is dated 24 September 2020.
|
Type | Announcement | Subject | OTHERS | Description | SOLUTION GROUP BERHAD ("SGB" or "THE COMPANY") LETTER OF AUTHORISATION FROM CANSINO BIOLOGICS INC. ("CanSino") | We refer to the Company’s announcements dated 19 August 2020, 24 August 2020, 27 August 2020, 2 September 2020, 23 September 2020 and 24 September 2020. The Board of Directors of Solution Group Berhad (“Board”) wishes to announce that our subsidiary, Solution Biologics Sdn Bhd (“SOLBIO”), had on 30 October 2020 received a Letter of Authorisation (“LOA”) from CanSino Biologics Inc. (“CanSino”, SHSE: 688185, HKEX:06185).
CanSino has authorized SOLBIO to develop the business in Philippines, Vietnam, Thailand, Myanmar, Cambodia, Laos and Brunei (“Territory”), for their Recombinant Novel Coronavirus Vaccine candidate (Ad5-nCoV) composed of an adenovirus type 5 vector (Bulk Product presentation) (“Bulk Product”), by working with the respective local partners, authorities and regulatory bodies in the Territory in order to prepare the market for the Bulk Product, so that the Product can be sold when it is approved.
Eventually, Malaysia will be the regional fill and finish hub for CanSino and supply the finished product to the Territory.
The LOA is valid for six (6) months with effective from 28 October 2020.
We attach a copy of the Company's Press Release for information.
This announcement is dated 30 October 2020. |
https://www.bursamalaysia.com/market_information/announcements/company_announcement/announcement_details?ann_id=3101400
|
|
|
|
|
|
|
|
|
|
|
|
发表于 14-2-2021 07:18 PM
来自手机
|
显示全部楼层
|
70sen进1.8卖。 后来又手痒1.65进， 1.28出。 |
|
|
|
|
|
|
|
|
|
|
|
楼主 |
发表于 14-5-2021 08:56 AM
|
显示全部楼层
本帖最后由 icy97 于 25-10-2021 08:19 AM 编辑
Type | Announcement | Subject | MULTIPLE PROPOSALS | Description | SOLUTION GROUP BERHAD ("SGB" OR THE "COMPANY") (i) PROPOSED DIVERSIFICATION; AND(ii) PROPOSED PRIVATE PLACEMENT(COLLECTIVELY, THE "PROPOSALS") | On behalf of the Board of Directors of SGB, M&A Securities Sdn Bhd wishes to announce that the Company proposes to undertake the following:
(i) proposed diversification of the existing business of SGB and its subsidiaries (“SGB Group” or the “Group”) to include the pharmaceutical related business (“Proposed Diversification”); and
(ii) proposed private placement of up to 30,732,600 new ordinary shares in SGB, representing not more than 10% of the total number of issued shares in SGB (“Proposed Private Placement”).
Please refer to the attachment for further details on the Proposals.
This announcement is dated 5 November 2020. |
https://www.bursamalaysia.com/market_information/announcements/company_announcement/announcement_details?ann_id=3103016
Type | Announcement | Subject | MULTIPLE PROPOSALS | Description | SOLUTION GROUP BERHAD ("SGB" OR THE "COMPANY") (i) PROPOSED DIVERSIFICATION; AND(ii) PROPOSED PRIVATE PLACEMENT(COLLECTIVELY, THE "PROPOSALS") | Unless otherwise defined in this announcement, all terms used herein shall have the same meaning as those defined in the announcement dated 5 November 2020 in relation to the Proposals (“Announcement”)
Further to the Announcement, M&A Securities, on behalf of the Board, wishes to announce the following further information in relation to the Proposals as set out in the attachment below.
This announcement is dated 18 November 2020. |
https://www.bursamalaysia.com/market_information/announcements/company_announcement/announcement_details?ann_id=3105916
Type | Announcement | Subject | MULTIPLE PROPOSALS | Description | SOLUTION GROUP BERHAD ("SGB" OR THE "COMPANY") (i) PROPOSED DIVERSIFICATION; AND(ii) PROPOSED PRIVATE PLACEMENT(COLLECTIVELY, THE "PROPOSALS") | Unless otherwise defined in this announcement, all terms used herein shall have the same meaning as those defined in the announcement dated 5 November 2020 in relation to the Proposals (“Announcement”)
Reference is made to the Company's additional announcement dated 18 November 2020 in relation to the Proposals ("Additional Announcement").
M&A Securities, on behalf of the Board, wishes to announce the amendment to the relevant sections of the Additional Announcement. Please refer to the attachment below for further details of the amendment to the Additional Announcement.
This announcement is dated 25 November 2020. |
https://www.bursamalaysia.com/market_information/announcements/company_announcement/announcement_details?ann_id=3107760
| 1. Details of Corporate Proposal | Involve issuance of new type/class of securities ? | No | Types of corporate proposal | Exercise of Warrants | Details of corporate proposal | Conversion of Warrants-A | No. of shares issued under this corporate proposal | 5,719,800 | Issue price per share ($$) | Malaysian Ringgit (MYR) 0.2000 | Par Value($$) (if applicable) |
| | Latest issued share capital after the above corporate proposal in the following | Units | 318,250,338 | Issued Share Capital ($$) | Malaysian Ringgit (MYR) 33,689,626.100 | Listing Date | 23 Nov 2020 |
SUMMARY OF KEY FINANCIAL INFORMATION
30 Sep 2020 |
| | INDIVIDUAL PERIOD | CUMULATIVE PERIOD | CURRENT YEAR QUARTER | PRECEDING YEAR
CORRESPONDING
QUARTER | CURRENT YEAR TO DATE | PRECEDING YEAR
CORRESPONDING
PERIOD | 30 Sep 2020 | 30 Sep 2019 | 30 Sep 2020 | 30 Sep 2019 | $$'000 | $$'000 | $$'000 | $$'000 |
| 1 | Revenue | 5,288 | 4,873 | 12,209 | 13,670 | | 2 | Profit/(loss) before tax | 577 | 235 | 322 | -98 | | 3 | Profit/(loss) for the period | 577 | 309 | 322 | -24 | | 4 | Profit/(loss) attributable to ordinary equity holders of the parent | 416 | 262 | 83 | -156 | | 5 | Basic earnings/(loss) per share (Subunit) | 0.14 | 0.09 | 0.03 | -0.05 | | 6 | Proposed/Declared dividend per share (Subunit) | 0.00 | 0.00 | 0.00 | 0.00 |
|
| AS AT END OF CURRENT QUARTER | AS AT PRECEDING FINANCIAL YEAR END | 7
| Net assets per share attributable to ordinary equity holders of the parent ($$) | 0.1244 | 0.1228
|
| 1. Details of Corporate Proposal | Involve issuance of new type/class of securities ? | No | Types of corporate proposal | Exercise of Warrants | Details of corporate proposal | Conversion of Warrants-A | No. of shares issued under this corporate proposal | 4,861,800 | Issue price per share ($$) | Malaysian Ringgit (MYR) 0.2000 | Par Value($$) (if applicable) |
| | Latest issued share capital after the above corporate proposal in the following | Units | 323,112,138 | Issued Share Capital ($$) | Malaysian Ringgit (MYR) 34,661,986.100 | Listing Date | 26 Nov 2020 |
| 1. Details of Corporate Proposal | Involve issuance of new type/class of securities ? | No | Types of corporate proposal | Private Placement | Details of corporate proposal | SOLUTION GROUP BERHAD ("SGB" OR THE "COMPANY") PRIVATE PLACEMENT OF UP TO 10% OF THE TOTAL ISSUED SHARES OF SGB ("PRIVATE PLACEMENT") | No. of shares issued under this corporate proposal | 30,857,600 | Issue price per share ($$) | Malaysian Ringgit (MYR) 0.9160 | Par Value($$) (if applicable) | Malaysian Ringgit (MYR) 0.000 | | Latest issued share capital after the above corporate proposal in the following | Units | 358,965,738 | Issued Share Capital ($$) | Malaysian Ringgit (MYR) 63,928,847.700 | Listing Date | 09 Dec 2020 |
Type | Announcement | Subject | OTHERS | Description | TERM SHEET BETWEEN THE MINISTRY OF HEALTH MALAYSIA ("MOH") AND SOLUTION BIOLOGICS SDN BHD ("SOLBIO"), A WHOLLY-OWNED SUBSIDIARY OF SOLUTION GROUP BERHAD ("SGB" or "THE COMPANY"), FOR THE SUPPLY OF THE COVID-19 VACCINE TO THE GOVERNMENT | INTRODUCTION The Board of Directors of Solution Group Berhad (“Board”) wishes to announce that the wholly-owned subsidiary Solution Biologics Sdn Bhd (“SOLBIO”), had on 29 January 2021 signed a Term Sheet Agreement with Government of Malaysia, represented by the Ministry of Health Malaysia (“MOH”) for the supply of the COVID-19 vaccine to the Government. The duly executed Term Sheet Agreement is to enable SOLBIO to enter into a definitive Supply Agreement to supply 3.5million doses of the Recombinant Ad5-nCoV vaccine (“Vaccine”) for the prevention of COVID-19. The Vaccine is jointly developed by CanSino Biologics Inc. (“CanSino”) and Beijing Institute of Biotechnology, Academy of Military Medical Sciences. MOH and SOLBIO hereinafter also individually referred to as “Party”, and collectively referred to as the “Parties”.
INFORMATION ON CANSINO CanSino is a biotech company in the People’s Republic of China, dedicated to developing novel vaccines and therapeutics for unmet medical needs. CanSino is developing a novel recombinant Ad5-nCoV vaccine composed of an adenovirus type 5 vector (liquid for injection).
SALIENT TERMS OF THE TERM SHEET AGREEMENT 1. The content of the Term Sheet Agreement represent an offer by either party to be used for preparing a definitive Supply Agreement between the parties. The Supply Agreement should be finalised and signed within 30 days after the Term Sheet Agreement is duly signed or within such extension of time as may be mutually agreed by the parties in writing. 2. The Vaccine will be delivered from SOLBIO storage facility to the Government appointed central store or logistics partner. 3. MOH to purchase 3.5 million vials of Vaccine from SOLBIO. The purchase is subject to the following milestones: i) SOLBIO obtaining the product registration and market authorization of the Vaccine in Malaysia from Drug Control Authority (“DCA”) by April 2021. ii) SOLBIO shall comply with the lot release requirement in Malaysia. iii) SOLBIO already hold Type A License under the Poison Act 1952 before the signing of the Supply Agreement. 4. MOH has the right to terminate this Term Sheet Agreement if the Purchase Milestones in Item (3) are not completed. 5. Neither of the parties may make any public announcement or disclosures regarding this term sheet or the agreement without the prior written approval of the other of the parties.
FINANCIAL EFFECTS OF THE AGREEMENT i) Share capital and shareholdings of substantial shareholders The Term Sheet Agreement will not have any effect on the share capital and substantial shareholders’ shareholdings of SGB as no new SGB shares will be issued pursuant to the Term Sheet Agreement. ii) Net Assets, Net Assets per share and gearing The Term Sheet Agreement is not expected to have any material effect on the net assets, net assets per share and gearing of the Group for the financial year ending 31 December 2021. iii) Earnings and Earnings Per Share Barring any unforeseen circumstances, and subject to the execution of the definitive Supply Agreement, and subject to the Vaccine being approved by the DCA, the Term Sheet Agreement is expected to contribute positively to the future earnings and EPS of SGB for the financial year ending 31 December 2021.
DIRECTORS AND MAJOR SHAREHOLDERS INTEREST None of the directors, substantial shareholders of the Company and persons connected to them has any interest, direct and/or indirect, in the Term Sheet Agreement.
APPROVALS REQUIRED The Term Sheet Agreement is not subject to the approval of shareholders of the Company. SOLBIO has obtained the Type A Poison License approval on 4 February 2021. SOLBIO has to obtain the product registration and market authorization of the vaccine in Malaysia from DCA by April 2021.
STATEMENT BY DIRECTORS The Board, having taken into consideration all aspects of the Term Sheet Agreement, is of the opinion that the Agreement is in the best interest of the SGB Group.
This announcement is dated 4 February 2021. |
|
|
|
|
|
|
|
|
|
|
|
|
楼主 |
发表于 28-11-2021 06:39 AM
|
显示全部楼层
Type | Announcement | Subject | OTHERS | Description | PRESS RELEASE ENTITLED "CANSINO'S COVID-19 VACCINE READY FOR BIGGER ROLLOUT TO THE PRIVATE MARKET AND AS BOOSTER SHOT" | We refer to the Company’s announcements dated 4 February 2021, 10 February 2021 and 1 April 2021. The Board of Directors of Solution Group Berhad wishes to announce that its wholly-owned subsidiary Solution Biologics Sdn Bhd (“SOLBIO”), the ASEAN manufacturing partner of CanSino Biologics Inc’s (“CanSino”) single-dose Convidecia, Recombinant Novel Coronavirus Vaccine (Adenovirus Type 5 Vector) (“Vaccine”), has to date completed the delivery of 2.6 million doses of the Vaccine to the Government. The remaining 300,000 and 600,000 doses are expected to be delivered in November and December 2021.
SOLBIO has submitted an application to National Pharmaceutical Regulatory Agency (NPRA) to register the Vaccine as a booster shot and hope to obtain the approval in November.
SOLBIO shall distribute the Vaccine to the private market, such as hospitals, clinics, the corporate and manufacturing sectors in Malaysia subject to the approval by the Ministry of Health (MOH).
The Company’s Press Release entitled “CanSino’s COVID-19 vaccine ready for bigger rollout to the private market and as booster shot" is enclosed for information.
This announcement dated 9 November 2021. |
https://www.bursamalaysia.com/market_information/announcements/company_announcement/announcement_details?ann_id=3207910
|
|
|
|
|
|
|
|
|
|
|
|
楼主 |
发表于 9-1-2022 08:43 AM
|
显示全部楼层
SUMMARY OF KEY FINANCIAL INFORMATION
30 Sep 2021 |
| | INDIVIDUAL PERIOD | CUMULATIVE PERIOD | CURRENT YEAR QUARTER | PRECEDING YEAR
CORRESPONDING
QUARTER | CURRENT YEAR TO DATE | PRECEDING YEAR
CORRESPONDING
PERIOD | 30 Sep 2021 | 30 Sep 2020 | 30 Sep 2021 | 30 Sep 2020 | $$'000 | $$'000 | $$'000 | $$'000 |
| 1 | Revenue | 31,777 | 5,288 | 45,911 | 12,209 | | 2 | Profit/(loss) before tax | 3,051 | 577 | 2,725 | 322 | | 3 | Profit/(loss) for the period | 3,051 | 577 | 1,559 | 322 | | 4 | Profit/(loss) attributable to ordinary equity holders of the parent | 2,080 | 416 | 862 | 83 | | 5 | Basic earnings/(loss) per share (Subunit) | 0.47 | 0.14 | 0.20 | 0.03 | | 6 | Proposed/Declared dividend per share (Subunit) | 0.00 | 0.00 | 0.00 | 0.00 |
|
| AS AT END OF CURRENT QUARTER | AS AT PRECEDING FINANCIAL YEAR END | 7
| Net assets per share attributable to ordinary equity holders of the parent ($$) | 0.1969 | 0.1940
|
|
|
|
|
|
|
|
|
|
|
|
|
楼主 |
发表于 6-9-2022 09:11 AM
|
显示全部楼层
Type | Announcement | Subject | OTHERS | Description | CANSINO'S RECOMBINANT COVID-19 VACCINE (ADENOVIRUS TYPE 5 VECTOR) FOR INHALATION HAS BEEN APPROVED BY THE NATIONAL MEDICAL PRODUCTS ADMINISTRATION OF PEOPLE'S REPUBLIC OF CHINA | The Board of Directors of Solution Group Berhad wishes to announce that its wholly-owned subsidiary Solution Biologics Sdn Bhd (“SOLBIO”), being the ASEAN manufacturing partner of CanSino Biologics Inc (“CanSino”) is pleased to announce that CanSino’s Recombinant COVID-19 Vaccine (Adenovirus Type 5 Vector) for Inhalation (“Ad5-nCoV for Inhalation” or “Convidecia Air™”) has been proposed by the National Health Commission of the People’s Republic of China (the “PRC”) and approved by the National Medical Products Administration of the PRC (the “NMPA”) for emergency use as a booster vaccine in the PRC.
Ad5-nCoV for Inhalation is a genetic engineered inhaled vaccine to prevent COVID-19 disease, it utilizing the same adenovirus vector technological platform as the intramuscular version Convidecia™, which can stimulate humoral and cellular immunity, and also induce mucosal immunity to establish the first line of defense in the respiratory tract and achieve triple comprehensive protection efficiently without intramuscular injection. Ad5-nCoV for Inhalation has unique advantages of safety, effectiveness, painlessness, convenience and availability. Convidecia Air™ is needle free which requiring only one fifth of the dosage of the intramuscular version.
On 12 August 2022, SOLBIO has received the approval from Ministry of Health of Malaysia's Medical Research and Ethics Committee ("MREC") to start a clinical trial in Malaysia, marking the first trial study of the inhaled version of COVID-19 vaccine in Malaysia to test the efficacy and safety of Ad5-nCoV for Inhalation as a second booster against various COVID-19 variants.
SOLBIO will be submitted an application to National Pharmaceutical Regulatory Agency (NPRA) to register Convidecia Air™ as a product.
The Company’s Press Release entitled “SGB Press Release-Convidecia Air Approval By NMPA_5Sep2022 " is enclosed for information
This announcement is dated 5 September 2022. |
https://www.bursamalaysia.com/market_information/announcements/company_announcement/announcement_details?ann_id=3290060
|
|
|
|
|
|
|
|
|
|
|
|
楼主 |
发表于 20-9-2023 12:07 PM
|
显示全部楼层
Type | Announcement | Subject | OTHERS | Description | Press Release entitled "Strategic Collaboration Accelerates: CanSino Invests in Solution Group Berhad, Fueling Advancements in Healthcare and Human Vaccine Development | Please find attached Solution Group Berhad's Press Release entitled "Strategic Collaboration Accelerates: CanSino Invests in Solution Group Berhad, Fueling Advancements in Healthcare and Human Vaccine Development”.
This announcement is dated 25 August 2023. |
https://www.bursamalaysia.com/market_information/announcements/company_announcement/announcement_details?ann_id=3379903
Type | Announcement | Subject | OTHERS | Description | Press Release entitled "Strategic Collaboration Accelerates: CanSino Invests in Solution Group Berhad, Fueling Advancements in Healthcare and Human Vaccine Development | Reference is made to Solution Group Berhad's Press Release entitled "Strategic Collaboration Accelerates: CanSino Invests in Solution Group Berhad, Fueling Advancements in Healthcare and Human Vaccine Development” dated 25 August 2023.
An amendment to the Press Release is made whereby the correct name of NIBM is National Institutes of Biotechnology Malaysia.
This announcement is dated 18 September 2023. |
https://www.bursamalaysia.com/market_information/announcements/company_announcement/announcement_details?ann_id=3385878
|
|
|
|
|
|
|
|
|
|
|
|
楼主 |
发表于 21-9-2023 03:46 PM
|
显示全部楼层
Type | Announcement | Subject | NEW ISSUE OF SECURITIES (CHAPTER 6 OF LISTING REQUIREMENTS)
FUND RAISING | Description | SOLUTION GROUP BERHAD ("SGB" OR THE "COMPANY")PROPOSED PRIVATE PLACEMENT OF UP TO 10% OF THE ISSUED SHARES IN SGB | On behalf of the Board of Directors of SGB, M&A Securities Sdn Bhd wishes to announce that the Company proposes to undertake a private placement of approximately 10% of the issued shares in SGB (“Proposed Private Placement”).
Kindly refer to the attachment on further details of the Proposed Private Placement.
This announcement is dated 25 August 2023. |
https://www.bursamalaysia.com/market_information/announcements/company_announcement/announcement_details?ann_id=3379731
Type | Announcement | Subject | NEW ISSUE OF SECURITIES (CHAPTER 6 OF LISTING REQUIREMENTS)
FUND RAISING | Description | SOLUTION GROUP BERHAD ("SGB" OR THE "COMPANY") PROPOSED PRIVATE PLACEMENT OF UP TO 10.0% OF THE TOTAL ISSUED ORDINARY SHARES IN SGB ("PROPOSED PRIVATE PLACEMENT") | (Unless otherwise defined, the definitions set out in the announcements dated 25 August 2023 shall apply herein)
Reference is made to the earlier announcements in relation to the Proposed Private Placement dated 25 August 2023 and 29 August 2023. M&A Securities, on behalf of the Board wishes to announce additional information in relation to the Proposed Private Placement.
Kindly refer to the attachment on further details of the Proposed Private Placement.
This announcement is dated 20 September 2023. |
https://www.bursamalaysia.com/market_information/announcements/company_announcement/announcement_details?ann_id=3386533
|
|
|
|
|
|
|
|
|
|
|
|
楼主 |
发表于 3-10-2023 05:31 AM
|
显示全部楼层
| 1. Details of Corporate Proposal | Involve issuance of new type/class of securities ? | No | Types of corporate proposal | Private Placement | Details of corporate proposal | Private Placement of up to 10% of the issued shares in SGB | No. of shares issued under this corporate proposal | 43,968,600 | Issue price per share ($$) | Malaysian Ringgit (MYR) 0.1950 | Par Value($$) (if applicable) |
| | Latest issued share capital after the above corporate proposal in the following | Units | 485,587,414 | Issued Share Capital ($$) | Malaysian Ringgit (MYR) 89,322,924.900 | Listing Date | 03 Oct 2023 |
|
|
|
|
|
|
|
|
|
|
|
|
楼主 |
发表于 4-10-2023 04:07 AM
|
显示全部楼层
Notice of Interest Sub. S-hldr (Section 137 of CA 2016)Particulars of Substantial Securities HolderName | CANSINO BIOLOGICS (HONG KONG) LIMITED | Address | Room 1901, 19/F, Lee Garden One
33 Hysan Avenue, Causeway Bay
Hong Kong. | Company No. | 3042973 | Nationality/Country of incorporation | Hong Kong | Descriptions (Class) | Ordinary Shares | Name of registered holder | M & A NOMINEE (ASING) SDN BHD - CANSINO BIOLOGICS (HONG KONG) LIMITED | Address of registered holder | 45-5, THE BOULEVARDMID VALLEY CITYLINGKARAN SYED PUTRA59200 KUALA LUMPUR |
| Date interest acquired & no of securities acquired | Date interest acquired | 02 Oct 2023 | No of securities | 43,968,600 | Circumstances by reason of which Securities Holder has interest | Subscription of shares via private placement | Nature of interest | Direct Interest |  | | Total no of securities after change | Direct (units) | 43,968,600 | Direct (%) | 9.091 | Indirect/deemed interest (units) | 0 | Indirect/deemed interest (%) | 0 | Date of notice | 03 Oct 2023 | Date notice received by Listed Issuer | 03 Oct 2023 |
|
|
|
|
|
|
|
|
|
|
|
|
楼主 |
发表于 14-9-2024 01:26 AM
|
显示全部楼层
SUMMARY OF KEY FINANCIAL INFORMATION
30 Jun 2024 |
| | INDIVIDUAL PERIOD | CUMULATIVE PERIOD | CURRENT YEAR QUARTER | PRECEDING YEAR
CORRESPONDING
QUARTER | CURRENT YEAR TO DATE | PRECEDING YEAR
CORRESPONDING
PERIOD | 30 Jun 2024 | 30 Jun 2023 | 30 Jun 2024 | 30 Jun 2023 | $$'000 | $$'000 | $$'000 | $$'000 |
| 1 | Revenue | 31,356 | 27,893 | 81,316 | 56,686 | | 2 | Profit/(loss) before tax | 432 | 589 | 1,411 | 1,080 | | 3 | Profit/(loss) for the period | -311 | 192 | 134 | 4 | | 4 | Profit/(loss) attributable to ordinary equity holders of the parent | -590 | -398 | -578 | -1,236 | | 5 | Basic earnings/(loss) per share (Subunit) | -0.13 | -0.09 | 0.13 | -0.28 | | 6 | Proposed/Declared dividend per share (Subunit) | 0.00 |
| 0.00 |
|
|
| AS AT END OF CURRENT QUARTER | AS AT PRECEDING FINANCIAL YEAR END | 7
| Net assets per share attributable to ordinary equity holders of the parent ($$) | 0.1747 | 0.1744
|
|
|
|
|
|
|
|
|
|
|
| |
 本周最热论坛帖子
|
1898 
47
![波德申禁止搭露营帐篷[+视频]](https://u2023.cari.com.my/data/avatar/001/55/96/42_avatar_small.jpg){kind=avatar}
